Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
The primary objective of the study is to compare the of OS rate at 12 months of Nivolumab combined with Ipilimumab to Sunitinib monotherapy in patients with previously untreated and advanced non-clear cell RCC.
Critère d'inclusion
- The primary objective of the study is to compare the of OS rate at 12 months of Nivolumab combined with Ipilimumab to Sunitinib monotherapy in patients with previously untreated and advanced non-clear cell RCC